Condition (MeSH)
Chondrosarcoma
ClinicalTrials.gov lists 97 trials for Chondrosarcoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
93 of the 97 trials are tagged with Chondrosarcoma itself; the rest are tagged with a narrower condition beneath it.
When did Chondrosarcoma trials start? (29)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 4 |
| 2024 | 5 |
| 2023 | 4 |
| 2022 | 2 |
| 2021 | 6 |
| 2020 | 7 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 3 |
Showing 10 of 29 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 57 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Chondrosarcoma trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 16 |
| Phase 1/2 | 11 |
| Phase 2 | 34 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Not applicable | 14 |
| Observational | 15 |
| Expanded access | 2 |
How many Chondrosarcoma trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 16 |
| Active, not recruiting | 8 |
| Available | 1 |
| Completed | 47 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Chondrosarcoma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 6 |
| SWOG Cancer Research Network | 3 |
| Eastern Cooperative Oncology Group | 2 |
| Valerio Therapeutics | 2 |
| AEterna Zentaris | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ifosfamid | 6 |
| Filgrastime (G-CSF) | 5 |
| Doxorubicine | 5 |
| Gemcitabine/Gemzar | 4 |
| Docetetaxel | 4 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Chondrosarcoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 43 | 6 |
| Pleural effusion | 36 | 5 |
| Vomiting | 36 | 8 |
| Fever | 30 | 4 |
| Nausea | 30 | 6 |
Showing 5 of 10 adverse events.
Which publications cover Chondrosarcoma? (77)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 77 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Chondrosarcoma | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Chondrosarcoma | Lifetime prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Chondrosarcoma | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Chondrosarcoma | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Chondrosarcoma | Lifetime prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Chondrosarcoma | 55880 | Exact | Orphadata Science knowledge files, Product 1 |
| Chondrosarcoma | 55880 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.